Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004198 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004198 is a Phase 2 study that has completed, run by University of Nebraska.
The verdict
NCT00004198, a Phase 2 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill tumor cells. Sargramostim may stimulate a person's immune system and help to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy plus sargramostim following chemotherapy in treating patients who have stage III or stage IV non-Hodgkin's lymphoma.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL keyhole limpet hemocyanin
- BIOLOGICAL tumor cell-based vaccine therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-06-25 |
| Est. Completion | 2003-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004198
The ClinicalTrials.gov registry entry for NCT00004198 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which sargramostim is the first listed.
NCT00004198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004198 about?
NCT00004198 is a clinical study titled "Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill tumor cells. Sargramostim may stimulate a person's immune system and help to kill tumor cells. PURPOSE: Phase II trial ...
What is the current status of trial NCT00004198?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-06-25. Estimated completion is 2003-11-20.
What interventions are being tested in trial NCT00004198?
The interventions under investigation include: sargramostim (BIOLOGICAL), keyhole limpet hemocyanin (BIOLOGICAL), tumor cell-based vaccine therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004198?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.